Zealand Pharma A/S Stock price

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Delayed Nasdaq Copenhagen 11:59:58 2024-03-27 am EDT 5-day change 1st Jan Change
681.5 DKK -2.36% Intraday chart for Zealand Pharma A/S -1.30% +82.61%
Sales 2024 * 806M 117M Sales 2025 * 1.29B 187M Capitalization 42.44B 6.15B
Net income 2024 * -358M -51.86M Net income 2025 * -256M -37.08M EV / Sales 2024 * 49.3 x
Net cash position 2024 * 2.69B 389M Net cash position 2025 * 2.77B 401M EV / Sales 2025 * 30.8 x
P/E ratio 2024 *
-119 x
P/E ratio 2025 *
-1,230 x
Employees 253
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.24%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.36%
1 week-1.30%
Current month+2.64%
1 month+9.92%
3 months+82.71%
6 months+128.84%
Current year+82.61%
More quotes
1 week
681.00
Extreme 681
723.50
1 month
631.50
Extreme 631.5
749.00
Current year
342.20
Extreme 342.2
749.00
1 year
205.60
Extreme 205.6
749.00
3 years
69.55
Extreme 69.55
749.00
5 years
69.55
Extreme 69.55
749.00
10 years
58.00
Extreme 58
749.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 09-12-31
Director of Finance/CFO - 22-10-31
Chief Operating Officer 52 18-02-28
Members of the board TitleAgeSince
Director/Board Member 66 19-04-03
Chairman 69 14-12-31
Director/Board Member 68 18-04-18
More insiders
Date Price Change Volume
24-03-27 681.5 -2.36% 290,377
24-03-26 698 -0.57% 225,463
24-03-25 702 -2.36% 179,157
24-03-22 719 +1.05% 232,033
24-03-21 711.5 +3.04% 575,472

Delayed Quote Nasdaq Copenhagen, March 27, 2024 at 11:59 am EDT

More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
681.5 DKK
Average target price
754.3 DKK
Spread / Average Target
+10.68%
Consensus
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen